Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Summary by AI BETAClose X

Ipsen has entered into an agreement to acquire Memo Therapeutics AG for an initial payment of 200 million EUR, with potential deferred payments exceeding 700 million EUR contingent on development, regulatory, and sales milestones, to secure the first-in-class BK polyomavirus antibody, potravitug. This clinical-stage asset, which targets BKPyVAN, a serious complication in kidney transplant patients, has shown promising efficacy in the Phase II SAFE KIDNEY II trial, with topline results indicating significant viral load reduction and histological improvement, supporting the initiation of a pivotal Phase II/III trial. The acquisition is expected to close in Q3 2026 and is factored into Ipsen's current full-year guidance, expanding its rare disease portfolio.

Disclaimer*

Companies

Ipsen SA (0MH6)
UK 100

Latest directors dealings